Condition: Refractory Heart Failure · Sponsor: Shenzhen Core Medical Technology CO.,LTD.
The primary objective of this study is to evaluate the safety and effectiveness of the Corheart 6 LVAS when used for the treatment of advanced left ventricular heart failure in a European population at 6 months post-implantation. The secondary objective is to assess the long-term safety and effectiveness of Corheart 6 LVAS treatment.
This description comes directly from the study's public registry record.
Xiaoli Shi · +86 13418601356 · shixiaoli@coretechmed.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Graz | Graz, Austria | Not Yet Recruiting |
| Universitätskliniken der MedUni Wien | Vienna, Austria | Recruiting |
| Herz-und Diabeteszentrum Nordrhein-Westfalen | Bad Oeynhausen, Germany | Recruiting |
| Deutsches Herzzentrum der Charité | Berlin, Germany | Recruiting |
| Klinikum Links der Weser | Bremen, Germany | Not Yet Recruiting |
| Universitätsklinikum Hamburg | Hamburg, Germany | Recruiting |
| Universitätsklinikums Heidelberg | Heidelberg, Germany | Recruiting |
| Herzzentrum Leipzig | Leipzig, Germany | Recruiting |
| Universitätsklinikum Würzburg | Würzburg, Germany | Not Yet Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Not Yet Recruiting |
| Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino | Torino, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05876000